Infobeans added healthcare as a vertical — after saying it hadn't
Q1 revenue rose 33% to ₹153 cr but margin slipped to 23%; management gave no FY27 revenue guidance and contradicted its own vertical focus statement.
What's new
- Q1 FY27 revenue ₹153 cr, up 33% YoY, 7% QoQ; EBITDA ₹35 cr, up 21% YoY.
- EBITDA margin 23%, below the 24% target, due to AI and sales investments ahead of revenue.
- AI-augmented software development at 43% of revenue, with accelerators and Claude partner network.
- Workforce at 1,800; 45 net additions in Q1.
Themes from the call
Demand
Strong Q1 growth with enterprise demand holding up, but management refused to quantify FY27 growth rate.
Margins
Margin pressure from upfront AI/sales investment; management expects return to 24% annually.
Capital allocation
No new geographies planned; acquisition focus on Salesforce/ServiceNow tech.
Guidance watch
- FY27 EBITDA margin target of 24% remains; quarterly delivery will not be linear.
- Three-year doubling goal through organic growth and acquisitions.
- AI and sales investment payback expected in 9-12 months.
- No percentage guidance for FY27 revenue growth.
Risk flags
- Revenue growth guidance absent despite strong Q1; uncertainty on sustainability.
- Margin recovery depends on timely conversion of AI/sales investments.
- Healthcare vertical addition unexplained; strategy credibility concern.
- One-time tax expense clouded PAT; no clean PAT margin disclosed.
Key quotes
-
"We usually target a 24.0% EBITDA margin every year, and we should be able to come back to that kind of number. That is the goal."
— InfoBeans management, Q&A on FY27 margins -
"We continue to focus only on two sectors right now: BFSI and storage and virtualization. And healthcare."
— InfoBeans management, Jul 2026 call
The brief
Infobeans delivered a strong Q1 — revenue up 33% to ₹153 cr, with AI-augmented work now 43% of the business. But two things keep the story from being clean. First, management first said it was sticking to BFSI and storage/virtualization as its verticals, then added healthcare in the same breath. The inconsistency is small in isolation but matters for credibility — especially since the same management declined to quantify FY27 revenue growth, leaving investors to guess how much of the Q1 momentum is sustainable. Second, EBITDA margin slipped to 23%, below the 24% annual target. The culprit is upfront investment in AI and US sales capacity, which management says takes 9-12 months to convert. That timeline makes sense, but with no growth rate commitment, the margin path is hostage to an uncertain revenue line. The three-year doubling goal and the Claude partnership are real levers, but they are years out. For now, investors are buying a solid quarter and a strategy that is still being built. It won't be a clear compounder until management commits to a number and sticks to its vertical story.
Infobeans' Q1 was strong but the missing growth guide and contradictory vertical focus make the story less clean than the top line suggests.